{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:30:56Z","timestamp":1784309456307,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T00:00:00Z","timestamp":1510790400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00277-017-3180-x","type":"journal-article","created":{"date-parts":[[2017,11,16]],"date-time":"2017-11-16T19:07:19Z","timestamp":1510859239000},"page":"277-287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["R-hyper-CVAD versus R-CHOP\/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20\u00a0years of single-center experience"],"prefix":"10.1007","volume":"97","author":[{"given":"Fabienne","family":"Widmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Balabanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Soldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus G.","family":"Manz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen S.","family":"Goede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,16]]},"reference":[{"key":"3180_CR1","first-page":"229","volume-title":"WHO-classification of tumours of haematopoietic and lymphoid tissues ,4th edn","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Seto M, M\u00fcller-Hermelink HK (2008) Mantle cell lymphoma. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO-classification of tumours of haematopoietic and lymphoid tissues ,4th edn. IARC Press, Lyon, pp 229\u2013232"},{"key":"3180_CR2","unstructured":"Federal Statistical Office (BFS), Section for demography and migration (2016) Population size and population composition. Federal Statistical Office Website. \nhttp:\/\/www.bfs.admin.ch\/bfs\/portal\/de\/index\/themen\/01\/02\/blank\/key\/bevoelkerungsstand\/01.html\n\n. Accessed 02 Aug 2016"},{"issue":"Suppl 3","key":"3180_CR3","doi-asserted-by":"publisher","first-page":"iii83","DOI":"10.1093\/annonc\/mdu264","volume":"25","author":"M Dreyling","year":"2014","unstructured":"Dreyling M, Geisler C, Hermine O, Kluin-Nelemans HC, le Gouill S, Rule S, Shpilberg O, Walewski J, Ladetto M, on behalf of the ESMO Guidelines Working Group (2014) Newly diagnosed and relapsed mantle cell lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl 3):iii83\u2013iii92. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdu264","journal-title":"Ann Oncol"},{"issue":"3","key":"3180_CR4","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","volume":"158","author":"C Geisler","year":"2012","unstructured":"Geisler C, Kolstad A, Laurell A et al (2012) Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 158(3):355\u2013362. \nhttps:\/\/doi.org\/10.1111\/j.1365-2141.2012.09174.x","journal-title":"Br J Haematol"},{"issue":"1","key":"3180_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/bjh.13796","volume":"172","author":"D Chihara","year":"2016","unstructured":"Chihara D, Cheah CY, Westin JR, Fayad LE, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak LW, Wang ML, Romaguera JE (2016) Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol 172(1):80\u201388. \nhttps:\/\/doi.org\/10.1111\/bjh.13796","journal-title":"Br J Haematol"},{"issue":"8","key":"3180_CR6","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ajh.24094","volume":"90","author":"JM Vose","year":"2015","unstructured":"Vose JM (2015) Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Am J Hematol 90(8):739\u2013745. \nhttps:\/\/doi.org\/10.1002\/ajh.24094","journal-title":"Am J Hematol"},{"issue":"7","key":"3180_CR7","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E, van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL network. Blood 105(7):2677\u20132684. \nhttps:\/\/doi.org\/10.1182\/blood-2004-10-3883","journal-title":"Blood"},{"issue":"2","key":"3180_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1111\/j.1365-2141.2010.08228.x","volume":"150","author":"JE Romaguera","year":"2010","unstructured":"Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M (2010) Ten-year follow-up after intense chemoimmunotherapy with rituximab-HyperCVAD alternating with rituximab-high dose methotrexate\/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150(2):200\u2013208. \nhttps:\/\/doi.org\/10.1111\/j.1365-2141.2010.08228.x","journal-title":"Br J Haematol"},{"issue":"6","key":"3180_CR9","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","volume":"24","author":"SH Bernstein","year":"2013","unstructured":"Bernstein SH, Epner E, Unger JM, LeBlanc M, Cebula E, Burack R, Rimsza L, Miller TP, Fisher RI (2013) A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol 24(6):1587\u20131593. \nhttps:\/\/doi.org\/10.1093\/annonc\/mdt070","journal-title":"Ann Oncol"},{"issue":"9","key":"3180_CR10","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1182\/blood-2011-07-369629","volume":"119","author":"AS LaCasce","year":"2012","unstructured":"LaCasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW (2012) Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL database. Blood 119(9):2093\u20132099. \nhttps:\/\/doi.org\/10.1182\/blood-2011-07-369629","journal-title":"Blood"},{"issue":"10","key":"3180_CR11","first-page":"1275","volume":"89","author":"F Lefr\u00e8re","year":"2004","unstructured":"Lefr\u00e8re F, Delmer A, Levy V, Delarue R, Varet B, Hermine O (2004) Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 89(10):1275\u20131276","journal-title":"Haematologica"},{"key":"3180_CR12","first-page":"965","volume":"116","author":"C Pott","year":"2010","unstructured":"Pott C, Hoster E, Beldjord K et al (2010) R-CHOP\/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: results of the MCL younger intergroup trial of the European MCL Network. ASH Annu Meet Abstr 116:965","journal-title":"ASH Annu Meet Abstr"},{"issue":"1","key":"3180_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","volume":"121","author":"R Delarue","year":"2013","unstructured":"Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H, Salles G, van Hoof A, Casasnovas O, Brousse N, Lefrere F, Hermine O, for the Groupe d'Etude des Lymphomes de l'Adulte (GELA) (2013) CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. Blood 121(1):48\u201353. \nhttps:\/\/doi.org\/10.1182\/blood-2011-09-370320","journal-title":"Blood"},{"issue":"4","key":"3180_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1365-2141.2008.07498.x","volume":"144","author":"MB Van\u2019t Veer","year":"2009","unstructured":"Van\u2019t Veer MB, de Jong D, MacKenzie M et al (2009) High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 144(4):524\u2013530. \nhttps:\/\/doi.org\/10.1111\/j.1365-2141.2008.07498.x","journal-title":"Br J Haematol"},{"issue":"10044","key":"3180_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"O Hermine","year":"2016","unstructured":"Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, H\u00e4nel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, D\u00fchrsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M (2016) Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European mantle cell lymphoma network. Lancet 388(10044):565\u2013575. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(16)00739-X","journal-title":"Lancet"},{"issue":"28","key":"3180_CR16","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"JE Romaguera","year":"2005","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Sarris AH, Dang NH, Wang M, Beasley V, Medeiros LJ, Katz RL, Gagneja H, Samuels BI, Smith TL, Cabanillas FF (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23(28):7013\u20137023. \nhttps:\/\/doi.org\/10.1200\/JCO.2005.01.1825","journal-title":"J Clin Oncol"},{"issue":"2","key":"3180_CR17","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, W\u00f6rmann B, Ludwig WD, D\u00fchrsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M, German Low Grade Lymphoma Study Group (GLSG), European Mantle Cell Lymphoma Network (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111(2):558\u2013565. \nhttps:\/\/doi.org\/10.1182\/blood-2007-06-095331","journal-title":"Blood"},{"issue":"14","key":"3180_CR18","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"n a listed","year":"1993","unstructured":"[no authors listed] (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med 329(14):987\u2013994. doi: \nhttps:\/\/doi.org\/10.1056\/NEJM199309303291402","journal-title":"N Engl J Med"},{"issue":"7","key":"3180_CR19","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","volume":"112","author":"CH Geisler","year":"2008","unstructured":"Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordstrom M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundstrom C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, for the Nordic Lymphoma Group (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112(7):2687\u20132693. \nhttps:\/\/doi.org\/10.1182\/blood-2008-03-147025","journal-title":"Blood"},{"issue":"5","key":"3180_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586. \nhttps:\/\/doi.org\/10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"key":"3180_CR21","unstructured":"National Institutes of Health and National Cancer Institute of the U.S. Department of Health and Human Services (2009) Common terminology criteria for adverse events (CTCAE) version 4.03. National Cancer Institute Enterprise vocabulary services. \nhttp:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf\n\n. Accessed 20 Mar 2016"},{"issue":"5","key":"3180_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F (1993) The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376. \nhttps:\/\/doi.org\/10.1093\/jnci\/85.5.365","journal-title":"J Natl Cancer Inst"},{"key":"3180_CR23","volume-title":"The EORTC QLQ-C30 scoring manual","author":"PM Fayers","year":"2001","unstructured":"Fayers PM, Aaronson NK, Bjordal K et al (2001) The EORTC QLQ-C30 scoring manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels","edition":"3"},{"issue":"1","key":"3180_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16(1):139\u2013144. \nhttps:\/\/doi.org\/10.1200\/JCO.1998.16.1.139","journal-title":"J Clin Oncol"},{"issue":"3","key":"3180_CR25","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1200\/JCO.1998.16.3.1188","volume":"16","author":"MJ Hjermstad","year":"1998","unstructured":"Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S (1998) Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ=C30 (+ 3). J Clin Oncol 16(3):1188\u20131196. \nhttps:\/\/doi.org\/10.1200\/JCO.1998.16.3.1188","journal-title":"J Clin Oncol"},{"issue":"11","key":"3180_CR26","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0959-8049(00)00447-0","volume":"37","author":"R Schwarz","year":"2001","unstructured":"Schwarz R, Hinz A (2001) Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 37(11):1345\u20131351. \nhttps:\/\/doi.org\/10.1016\/S0959-8049(00)00447-0","journal-title":"Eur J Cancer"},{"issue":"3","key":"3180_CR27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","volume":"156","author":"F Merli","year":"2012","unstructured":"Merli F, Luminari S, Ilariucci F, Petrini M, Visco C, Ambrosetti A, Stelitano C, Caracciolo F, di Renzo N, Angrilli F, Carella AM, Capodanno I, Barbolini E, Galimberti S, Federico M (2012) Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 156(3):346\u2013353. \nhttps:\/\/doi.org\/10.1111\/j.1365-2141.2011.08958.x","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3180-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3180-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3180-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T04:38:09Z","timestamp":1515040689000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3180-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,16]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["3180"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3180-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,16]]}}}